Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.
Onco Targets Ther
; 7: 469-76, 2014.
Article
in En
| MEDLINE
| ID: mdl-24711703
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Onco Targets Ther
Year:
2014
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Nueva Zelanda